SGSH (N-sulfoglucosamine sulfohydrolase) Drug Discovery Landscape & Assay Solutions
- By admin
- 08 Aug 2026
- Comments
Enzyme Replacement & Gene Therapy Development for Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A)
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SGSH-targeting rare disease drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | SGSH Recombinant Protein (Wild-type) High purity (>95%), HEK293 expressed (Native Glycosylation), Endotoxin <1 EU/µg. Sequence Verified. |
View SGSH Products |
| Mutant Panel | SGSH Disease Variants (R74C, R245H, S66W) Pathogenic mutations for mechanism and loss-of-function studies. Theoretical MW verified. |
View SGSH Products |
| Gene Delivery | SGSH Lentivirus Particles (ORF) Full-length ORF for stable cell line construction (HEK293T, Fibroblast). |
View SGSH Products |
| Benchmark Antibody | Anti-SGSH Control Antibody Recombinant positive control for expression assays. |
View SGSH Products |
| PK/PD Assay | Anti-SGSH Polyclonal Antibody For pharmacokinetic detection and immunogenicity (ADA) screening. |
View SGSH Products |
| Validator | SGSH siRNA Set For specific knockdown and uptake mechanism verification. |
View SGSH Products |
| SUMF1 (Related) | Essential activating enzyme for sulfatases (generates formylglycine) – required for SGSH catalytic activity. | View SUMF1 Products |
| NAGLU (Sanfilippo C) | Alpha-glucosaminide N-acetyltransferase Alternative MPS III target for cross-species assay validation. |
View NAGLU Products |
| GNS (Sanfilippo B) | N-acetylglucosaminidase Parallel pathway enzyme; comparator for substrate reduction studies. |
View GNS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mannose-6-Phosphate (M6P) Uptake & Lysosomal Targeting | HEK293 Expressed Proteins with native glycosylation patterns; confirmed M6P tagging for efficient CI-M6PR binding and cellular uptake. |
| Cross-species Preclinical Evaluation (Mouse/Cyno/Human) | Human/Mouse/Cyno SGSH ortholog proteins available with >95% purity; sequence alignment verified by mass spec. |
| Immunogenicity (ADA) Screening & Epitope Mapping | High-purity wild-type and mutant proteins for antibody binding epitope mapping; positive control antibodies included. |
| Enzymatic Activity Standardization & Stability | Sequence-verified reference standard with defined specific activity units; high purity (>95%) and endotoxin control (<1 EU/µg) preserve structural integrity and activity. |
| BBB Transcytosis & Cellular Uptake Assays (Fusion Proteins) | Full-length SGSH ORF Lentivirus for stable reporter cell lines; validated siRNA for specificity controls to prevent false positives. |
Live SGSH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (MPS IIIA)
- ➤ Latest Gene Therapy Research
- ➤ Recent Patent Filings (Enzyme & AAV vectors)
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Sanfilippo Syndrome A is undergoing a paradigm shift from palliative care toward curative interventions. First-generation Enzyme Replacement Therapies (ERT) face challenges with blood-brain barrier (BBB) penetration, driving investment toward novel delivery systems (e.g., BBB-crossing fusion proteins targeting the Transferrin receptor) and AAV-mediated central nervous system gene therapies. Major players such as Lysogene (LYS-SAF302) and Sarepta are advancing gene therapy programs through Phase II/III, while JCR Pharmaceuticals and Denali Therapeutics pursue BBB-penetrant fusion proteins. The next wave of R&D focuses on substrate reduction therapies (SRT) as adjunct treatments, and next-generation ERTs with enhanced M6P density for improved neuronal uptake. Neonatal screening expansion is expected to shift trial endpoints toward neurocognitive preservation rather than halting progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | Lysogene, Sarepta, Esteve | MPS IIIA (Pediatric) | SGSH Expression Validation (Need high-purity antigen for titer/PK) |
| Enzyme Replacement (ERT) | JCR Pharmaceuticals, JKV Biotech, BioMarin | MPS IIIA (Systemic/CNS) | Cellular Uptake Assay (Need M6P-tagged protein for receptor binding); PK/PD detection |
| BBB-Penetrant Fusion | Denali Therapeutics | Neurological Lysosomal Storage | Transcytosis Validation (Need Sequence Verified, High Purity Antigens) |
| Substrate Reduction | Seelos Therapeutics, Sarepta | MPS IIIA (Adjunct) | Enzymatic Activity Assay (Need active SGSH as comparator) |
| Neonatal Screening | PerkinElmer, Sanofi | Newborn diagnosis | Mutant Protein Controls (Need disease variants for assay validation) |